A5000087639- Mechanical Circulatory Support Devices
- Cardiac Structural Anomalies and Repair
- Cardiovascular Function and Risk Factors
- Heart Failure Treatment and Management
- Cardiac Arrest and Resuscitation
- Cardiac Ischemia and Reperfusion
- Cardiac Valve Diseases and Treatments
- Congenital Heart Disease Studies
- Mitochondrial Function and Pathology
- Cardiac Imaging and Diagnostics
- Cardiac pacing and defibrillation studies
- Transplantation: Methods and Outcomes
- Fuel Cells and Related Materials
- Cardiovascular and Diving-Related Complications
- Cardiac Health and Mental Health
- Pulmonary Hypertension Research and Treatments
- Renal Transplantation Outcomes and Treatments
- Cardiac and Coronary Surgery Techniques
- Cardiac electrophysiology and arrhythmias
- Traumatic Brain Injury Research
- Cardiovascular Effects of Exercise
- Erythropoietin and Anemia Treatment
- Vibrio bacteria research studies
- ATP Synthase and ATPases Research
- Hematological disorders and diagnostics
University of Utah
2013-2025
Intermountain Healthcare
2024
Intermountain Medical Center
2024
University of Utah Health Care
2014-2021
LDS Hospital
2012-2021
Johnson University
2021
Harrison Medical Center
2021
University of Utah Hospital
2013-2016
National and Kapodistrian University of Athens
2005-2009
Alexandra Hospital
2005
In recent years, there have been significant advancements in the understanding, risk-stratification, and treatment of cardiogenic shock (CS). Despite improved pharmacologic device-based therapies for CS, short-term mortality remains as high 50%. Most efforts research focused on CS related to acute myocardial infarction, even though heart failure (HF-CS) accounts >50% cases. There is a paucity high-quality evidence support standardized clinical practices approach HF-CS. addition, an unmet...
The clinical therapy for treating acute myocardial infarction is primary percutaneous coronary intervention (PPCI). PPCI effective at reperfusing the heart, however rapid re-introduction of blood can cause ischemia-reperfusion (I/R). Reperfusion injury responsible up to half final damage, but there are no pharmacological interventions reduce I/R. We previously demonstrated that inhibiting monocarboxylate transporter 4 (MCT4) and re-directing pyruvate towards oxidation blunt hypertrophy....
Importance The advanced ambulatory heart failure (HF) population comprises patients who have progressed beyond the pillars of recommended stage C HF therapies but can still find meaningful life-years ahead. Although these are commonly encountered in practice, national databases selectively capture small groups accepted for transplant listing or left ventricular assist devices. epidemiology, trajectories, and other with poorly understood. Observations In December 2022, National Heart, Lung...
Ischemic heart disease and acute myocardial infarction (AMI) is a leading cause of morbidity mortality. Improvements have been made in coronary interventions to restore blood flow, but ischemia/reperfusion (I/R) injury significantly impacts clinical outcomes. We previously reported that activation percutaneous mechanical unloading the left ventricle (LV) with transvalvular axial-flow device simultaneously reperfusion improves salvage. However, underlying mechanisms, potential adjuvant...
The established clinical therapy for the treatment of acute myocardial infarction is primary percutaneous coronary intervention (PPCI) to restore blood flow ischemic myocardium. PPCI effective at reperfusing myocardium, however rapid re-introduction oxygenated also can cause ischemia-reperfusion (I/R) injury. Reperfusion injury culprit up half final damage, but there are no interventions reduce I/R We previously demonstrated that inhibiting lactate exporter, monocarboxylate transporter 4...
Abstract Lactate is the highest turnover circulating metabolite in mammals. While traditionally viewed as a waste product, lactate an important energy source for many organs, but first must be oxidized to pyruvate entry into tricarboxylic acid cycle (TCA cycle). This reaction thought occur cytosol, with subsequently transported mitochondria via mitochondrial carrier (MPC). Using 13 C stable isotope tracing, we demonstrated that myocardial tissue of mice even when MPC genetically deleted....
Background: Acute myocardial ischemia and the mode of ventricular fibrillation (VF) induction influence defibrillation threshold (DFT). Objectives: The purpose this study was to determine effects transient regional left (LV) on DFT. Methods: Ventricular effective refractory period (ERP), (VFT), DFT were measured under nonischemic conditions (control) in 26 pigs weighing 25–35 kg. Myocardial then induced by occlusion mid anterior descending coronary artery, measurements ERP VFT repeated after...
Levosimendan (LEVO), a new inodilator, improves hemodynamic function in patients with decompensated heart failure and preserved arterial blood pressure. Data on its use cardiogenic shock (CS) are scarce. The present study was undertaken to evaluate the effects of supplemental therapy levosimendan (LEVO) acute myocardial infarction (MI) refractory (CS).In 25 presenting CS after MI, LEVO administered for 24 h doses ranging between 0.05 0.20 microg/kg/min, as tolerated, preceded by 6-microg/kg...
A growing proportion of transplant donors and recipients have a history COVID-19 infection. This study sought to characterize clinical practice after recipient or donor infection.An online survey was distributed heart clinicians through professional society message board social media. Responses were collected between September 29 November 5, 2021.There 222 health care professionals (68% cardiologists, 22% surgeons, 10% other) across diverse geographic regions who completed the survey. While...
Heart failure (HF) involves global genome modifications. Adverse structural and function remodeling that occurs in HF was initially considered to be irreversible. However, ~15% of patients on left ventricular assist device (LVAD) support show significant functional reverse remodeling, distinguishing them as responders (R), while ~85% are non-responders (NR). DNA methylation transcriptional changes exert myocardial recovery is not well understood. To address this, we performed whole-genome...
Abstract Background A subset of advanced heart failure (HF) patients can experience significant improvement in their cardiac structure and function while on left ventricular assist device (LVAD) support, which is among the prerequisites for LVAD weaning. Purpose We sought to develop validate a predictive personalized tool identify candidates HF therapies with high potential achieve myocardial post-LVAD. This aid clinicians considering options. Methods total 884 consecutive were enrolled. The...
Abstract Background A subset of heart failure (HF) patients can experience significant improvement their cardiac structure and function while on left ventricular assist device (LVAD) support. Purpose We sought to investigate the impact HF etiology durability favorable outcomes after LVAD weaning. Methods studied 324 enrolled in international multicenter VAD Wean Registry who received a durable continuous-flow underwent support weaning (Figure 1). Indications for included:...